Mammoth Biosciences is developing a turnkey workstation to run a CRISPR-based SARS-CoV-2 molecular assay based on automated liquid handling equipment. This high throughput system can perform up to 1,500 tests per shift with minimal user interaction. CLIA high complexity laboratories will be able to significantly increase capacity with minimal FTE support to meet increasing demand. Learn more from our recent press release.
*This product has not been evaluated by the Food and Drug Administration and no emergency use authorization has been granted. Mammoth Biosciences is intending to submit for FDA EUA.